JP2020512977A - Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ - Google Patents

Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ Download PDF

Info

Publication number
JP2020512977A
JP2020512977A JP2019553068A JP2019553068A JP2020512977A JP 2020512977 A JP2020512977 A JP 2020512977A JP 2019553068 A JP2019553068 A JP 2019553068A JP 2019553068 A JP2019553068 A JP 2019553068A JP 2020512977 A JP2020512977 A JP 2020512977A
Authority
JP
Japan
Prior art keywords
cancer
compound
inhibitor
subject
wee1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512977A5 (cg-RX-API-DMAC7.html
Inventor
アレックス ヴォ，
アレックス ヴォ，
ケビン クルカー，
ケビン クルカー，
スコット ピーターソン，
スコット ピーターソン，
Original Assignee
シアトル ジェネティックス， インコーポレイテッド
シアトル ジェネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティックス， インコーポレイテッド, シアトル ジェネティックス， インコーポレイテッド filed Critical シアトル ジェネティックス， インコーポレイテッド
Publication of JP2020512977A publication Critical patent/JP2020512977A/ja
Publication of JP2020512977A5 publication Critical patent/JP2020512977A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019553068A 2017-03-31 2018-03-30 Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ Pending JP2020512977A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480101P 2017-03-31 2017-03-31
US62/480,101 2017-03-31
PCT/US2018/025464 WO2018183891A1 (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Publications (2)

Publication Number Publication Date
JP2020512977A true JP2020512977A (ja) 2020-04-30
JP2020512977A5 JP2020512977A5 (cg-RX-API-DMAC7.html) 2021-05-13

Family

ID=62002508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553068A Pending JP2020512977A (ja) 2017-03-31 2018-03-30 Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ

Country Status (11)

Country Link
US (1) US20200108074A1 (cg-RX-API-DMAC7.html)
EP (1) EP3600247A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512977A (cg-RX-API-DMAC7.html)
KR (1) KR20190130621A (cg-RX-API-DMAC7.html)
CN (1) CN110678169A (cg-RX-API-DMAC7.html)
AU (1) AU2018243667A1 (cg-RX-API-DMAC7.html)
CA (1) CA3058457A1 (cg-RX-API-DMAC7.html)
IL (1) IL269409A (cg-RX-API-DMAC7.html)
MX (1) MX2019011506A (cg-RX-API-DMAC7.html)
SG (1) SG11201908788YA (cg-RX-API-DMAC7.html)
WO (1) WO2018183891A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
US20220387468A1 (en) * 2019-10-25 2022-12-08 Astrazeneca Ab Methods of treating cancer
AU2021226119B2 (en) * 2020-02-27 2024-04-18 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
CN115778962B (zh) * 2022-11-28 2024-09-17 中国医学科学院肿瘤医院 治疗男性食管癌患者的药物及其相关应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039854A1 (en) * 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP2013542997A (ja) * 2010-11-16 2013-11-28 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
WO2015120390A1 (en) * 2014-02-10 2015-08-13 Oncothyreon Inc. Pharmaceutical compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003010444A1 (en) 2001-07-23 2003-02-06 Shock-Proof Solutions Pty Ltd Mechanical shock absorbing apparatus
CA2532231A1 (en) 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050176733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
CA2573063A1 (en) 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting chk1
AU2005272586A1 (en) 2004-08-19 2006-02-23 Icos Corporation Compounds useful for inhibiting CHK1
CA2602199C (en) * 2005-03-29 2013-09-10 Icos Corporation Heteroaryl urea derivatives useful for inhibiting chk1
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US20100113445A1 (en) 2007-03-20 2010-05-06 Smithkline Beecham Corporation Chemical Compounds
PT2168966T (pt) 2007-06-15 2017-01-02 Msd Kk Derivado de bicicloanilina
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
WO2010098367A1 (en) 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
ES2606640T3 (es) 2012-02-23 2017-03-24 Abbvie Inc. Inhibidores de cinasas de tipo piridopirimidinona
KR20210156333A (ko) * 2012-05-15 2021-12-24 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017216559A1 (en) 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542997A (ja) * 2010-11-16 2013-11-28 アレイ バイオファーマ、インコーポレイテッド チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
WO2013039854A1 (en) * 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2015120390A1 (en) * 2014-02-10 2015-08-13 Oncothyreon Inc. Pharmaceutical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOTARGET, vol. 6, no. 5, JPN6021050183, 2015, pages 3394 - 3408, ISSN: 0004815598 *

Also Published As

Publication number Publication date
KR20190130621A (ko) 2019-11-22
SG11201908788YA (en) 2019-10-30
CN110678169A (zh) 2020-01-10
US20200108074A1 (en) 2020-04-09
EP3600247A1 (en) 2020-02-05
IL269409A (en) 2019-11-28
WO2018183891A1 (en) 2018-10-04
AU2018243667A1 (en) 2019-10-17
CA3058457A1 (en) 2018-10-04
MX2019011506A (es) 2019-11-01

Similar Documents

Publication Publication Date Title
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
JP6575952B2 (ja) イブルチニブ併用療法
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US20160193211A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
KR20190077441A (ko) 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료
US20190290652A1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
AU2009254554B2 (en) Pharmaceutical combination
ES3040063T3 (en) Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
KR20120117943A (ko) 항암 치료 방법
US20220323470A1 (en) Composition and use thereof in the manufacture of medicament for treating cancer
Socinski Pemetrexed (Alimta) in small cell lung cancer
CN120202006A (zh) 卡帕塞替尼和维奈托克的治疗组合
HK40009222A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
TW201311247A (zh) 包括末期或轉移固態惡性腫瘤之固態惡性腫瘤治療
AU2015210337A1 (en) Pharmaceutical combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220701